Monday, March 29, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
FDA Approval of PoNS for MS

Helius Medical Technologies Inc are a medical technology company. It is focused on the development of products for the treatment of neurological symptoms caused by disease or trauma. The company has developed its first, known as the portable neuromodulation stimulator or PoNS, device, is designed to enhance the brain’s ability to compensate for this damage.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FDA Approval. On Friday, the U.S. Food and Drug Administration authorized marketing of the PoNS device for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. With over one million MS patients in the U.S., this is the largest market for which the PoNS treatment has received approval.


FDA Comment.  According to Christopher M. Loftus, M.D., acting director of the Office of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health, “MS is one of the most common neurological diseases in young adults. Today’s authorization offers a valuable new aid in physical therapy and increases the value of additional therapies for those who live with MS …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.